IN2014DN08537A - - Google Patents

Download PDF

Info

Publication number
IN2014DN08537A
IN2014DN08537A IN8537DEN2014A IN2014DN08537A IN 2014DN08537 A IN2014DN08537 A IN 2014DN08537A IN 8537DEN2014 A IN8537DEN2014 A IN 8537DEN2014A IN 2014DN08537 A IN2014DN08537 A IN 2014DN08537A
Authority
IN
India
Prior art keywords
pneumonia
heart failure
monitoring
treatment
categorizing
Prior art date
Application number
Other languages
English (en)
Inventor
Christopher Joseph Pemberton
Arthur Mark Richards
Mathew Simon Byers
Original Assignee
Otago Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otago Innovation Ltd filed Critical Otago Innovation Ltd
Publication of IN2014DN08537A publication Critical patent/IN2014DN08537A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/63—Motilins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
IN8537DEN2014 2012-03-20 2013-03-15 IN2014DN08537A (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613311P 2012-03-20 2012-03-20
PCT/NZ2013/000043 WO2013141716A1 (en) 2012-03-20 2013-03-15 Biomarkers

Publications (1)

Publication Number Publication Date
IN2014DN08537A true IN2014DN08537A (hr) 2015-05-15

Family

ID=49223053

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8537DEN2014 IN2014DN08537A (hr) 2012-03-20 2013-03-15

Country Status (7)

Country Link
US (1) US10114028B2 (hr)
EP (1) EP2828282B1 (hr)
CN (1) CN104470942B (hr)
DK (1) DK2828282T3 (hr)
ES (1) ES2661516T3 (hr)
IN (1) IN2014DN08537A (hr)
WO (1) WO2013141716A1 (hr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104107419A (zh) * 2014-05-29 2014-10-22 四川大学华西医院 胃饥饿素在预防或/和治疗放射性肺损伤中的用途
CA3092519A1 (en) * 2018-03-02 2019-09-06 Evonik Operations Gmbh In vitro method for detecting intestinal barrier failure in animals by determining ovotransferrin
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
CN109825567B (zh) * 2018-12-27 2022-06-10 博奥生物集团有限公司 肺炎诊断用circRNA生物标志物及应用、引物和试剂
CN111951215A (zh) * 2020-06-30 2020-11-17 数坤（北京）网络科技有限公司 一种图像检测方法、装置及计算机可读存储介质
CN117393154B (zh) * 2023-12-12 2024-03-01 中国中医科学院医学实验中心 基于血清全通路氧化脂质组学筛选心力衰竭生物标志物的方法及应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5310687A (en) 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
US5843708A (en) 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
WO1991017440A1 (en) 1990-05-07 1991-11-14 Immunomedics, Inc. Improved method for radiolabeling monovalent antibody fragments
WO1992005282A1 (en) 1990-09-14 1992-04-02 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5221685A (en) 1991-02-01 1993-06-22 Ube Industries, Ltd. Thiazoline derivative, process for preparing the same and chemical for controlling noxious organisms containing the same
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
DE69228682T2 (de) 1991-04-10 1999-07-01 Biosite Diagnostics Inc., San Diego, Calif. "crosstalk"- oder übersprech-inhibitoren und ihre verwendung
WO1992018866A1 (en) 1991-04-10 1992-10-29 Biosite Diagnostics Incorporated Novel conjugates and assays for simultaneous detection of multiple ligands
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
DK0700521T3 (da) 1993-05-28 2003-09-29 Baylor College Medicine Fremgangsmåde og massespektrometer til desorption og ionisering af analysander
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
DK0653625T3 (da) 1993-11-12 2003-01-13 Inverness Medical Switzerland Aflæseindretninger til teststrimler
EP0653639B1 (en) 1993-11-12 2000-03-22 Unilever Plc Analytical devices and methods of use thereof
US5647124A (en) 1994-04-25 1997-07-15 Texas Instruments Incorporated Method of attachment of a semiconductor slotted lead to a substrate
GB9419267D0 (en) 1994-09-23 1994-11-09 Unilever Plc Assay devices
US5792294A (en) 1995-11-16 1998-08-11 Otis Elevator Company Method of replacing sheave liner
US5719600A (en) 1995-12-12 1998-02-17 Hewlett-Packard Company Gradient calculation system and method
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
GB9717926D0 (en) 1997-08-22 1997-10-29 Micromass Ltd Methods and apparatus for tandem mass spectrometry
AU2463299A (en) 1998-01-23 1999-08-09 Analytica Of Branford, Inc. Mass spectrometry from surfaces
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6831060B2 (en) 1999-05-07 2004-12-14 Genentech, Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
WO2003054543A2 (en) 2001-12-21 2003-07-03 Sense Proteomic Limited Probe for mass spectrometry
AUPS169202A0 (en) 2002-04-11 2002-05-16 Goetze, Jens Peter Neuropeptide assay
US6780645B2 (en) 2002-08-21 2004-08-24 Lifescan, Inc. Diagnostic kit with a memory storing test strip calibration codes and related methods
US7045366B2 (en) 2003-09-12 2006-05-16 Ciphergen Biosystems, Inc. Photocrosslinked hydrogel blend surface coatings
US20040091961A1 (en) 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
CA2522709A1 (en) 2003-04-17 2004-11-04 Ciphergen Biosystems, Inc. Polypeptides related to natriuretic peptides and methods of their identification and use
CA2530393A1 (en) 2003-07-02 2005-01-13 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2005052593A1 (en) 2003-10-29 2005-06-09 The University Of Leicester Detection
US7423139B2 (en) 2004-01-20 2008-09-09 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5′-UTR
NZ552667A (en) 2004-07-23 2009-04-30 Inst Medical W & E Hall Therapeutic and diagnostic agents
WO2006015371A2 (en) 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
JP2006292623A (ja) 2005-04-13 2006-10-26 Univ Of Dundee 心不全における突然死のマーカー
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
AU2007293777B2 (en) 2006-09-07 2014-03-20 Otago Innovation Limited Biomarkers
GB0712670D0 (en) 2007-06-29 2007-08-08 King S College London Isolated peptides and uses thereof
CA2715921A1 (en) * 2008-03-12 2009-09-17 Otago Innovation Limited Biomarkers
US20120220493A1 (en) * 2009-10-21 2012-08-30 Pronota N.V. Biomarker for diagnosis, prediction and/or prognosis of acute heart failure and uses thereof

Also Published As

Publication number Publication date
CN104470942A (zh) 2015-03-25
EP2828282A1 (en) 2015-01-28
EP2828282B1 (en) 2017-12-27
EP2828282A4 (en) 2015-08-26
WO2013141716A1 (en) 2013-09-26
CN104470942B (zh) 2018-12-14
ES2661516T3 (es) 2018-04-02
DK2828282T3 (en) 2018-03-05
US10114028B2 (en) 2018-10-30
US20130296240A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
IN2014DN08537A (hr)
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
WO2013008102A3 (en) Methods and compositions for evaluating and/or treating chronic immune diseases
BR112014031365A2 (pt) métodos de detectar doenças ou condições
EA201071324A1 (ru) Система и способы измерения профилей биомаркеров
GB2488700B (en) Methods for monitoring disease conditions by analysis of the full repertoire of CDR3 sequences of an individual
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
WO2014028884A3 (en) Cancer diagnostics using biomarkers
EP2566983A4 (en) SERIAL ANALYSIS OF BIOMARKERS FOR THE DIAGNOSIS OF A DISEASE
GB201021399D0 (en) Oligonucleotide probe set and methods of microbiota profiling
IN2014CN04326A (hr)
WO2011047033A3 (en) Biomarker for identification of melanoma tumor cells
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
CA2798431C (en) Monitoring health and disease status using clonotype profiles
EA201290711A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
BR112012012513A2 (pt) método para diagnosticar síndrome do intestino irritável em um paciente, método para monitorar a progressão ou regressão da síndrome do intestino irritável em um paciente, e para designar uma terapia contra síndrome do intestino irritável a um paciente em necessidade do mesmo
WO2015006489A8 (en) Blood-based screen for detecting neurological diseases in primary care settings
MX2021012347A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
EP2756313A4 (en) METHOD AND KITS FOR DETECTING AND MONITORING DIAGNOSTIC BIOMARKERS FOR POSTTRAUMATIC LOAD DISORDER (PTSD) AND DISTINCTION BETWEEN SUICID AND NON-SUCCIDANT FORMS OF DISORDER
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
NZ729773A (en) Biomarkers for disease progression in melanoma
EA201790696A1 (ru) Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности